The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study.
about
Burns: an update on current pharmacotherapyGlycemic variability and glycemic control in the acutely ill cardiac patientIncretins and the intensivist: what are they and what does an intensivist need to know about them?Evaluation of intragastric vs intraperitoneal glucose tolerance tests in the evaluation of insulin resistance in a rodent model of burn injury and glucagon-like polypeptide-1 treatmentThe gut-brain axis in the critically ill: is glucagon-like peptide-1 protective in neurocritical care?Impact of early versus late enteral nutrition on cell mediated immunity and its relationship with glucagon like peptide-1 in intensive care unit patients: a prospective studyThe potential role of incretin therapy in the hospital setting.The use of exenatide in severely burned pediatric patients.Effects of glucose-dependent insulinotropic polypeptide on gastric emptying, glycaemia and insulinaemia during critical illness: a prospective, double blind, randomised, crossover study.Bench-to-bedside review: the gut as an endocrine organ in the critically illThe therapeutic potential of a venomous lizard: the use of glucagon-like peptide-1 analogues in the critically illYear in review 2009: Critical Care--metabolism.Exogenous glucagon-like peptide-1 attenuates the glycaemic response to postpyloric nutrient infusion in critically ill patients with type-2 diabetes.Pharmacotherapy for Hyperglycemia in Noncritically Ill Hospitalized PatientsThe incretin effect in critically ill patients: a case-control study.The effect of exogenous glucose-dependent insulinotropic polypeptide in combination with glucagon-like peptide-1 on glycemia in the critically ill.Incretin-based therapies: new treatments for type 2 diabetes in the new millennium.Incretins in the ICU: is insulin on its way out?Incretin-based therapies: review of the outpatient literature with implications for use in the hospital and after discharge.Bench-to-bedside review: Glucose and stress conditions in the intensive care unitWaking up the gut in critically ill patients.Burns: where are we standing with propranolol, oxandrolone, recombinant human growth hormone, and the new incretin analogs?Exogenous glucagon-like peptide-1 for hyperglycemia in critically ill patients.Dysglycaemia in the critically ill - significance and management.Review article: the role of gastrointestinal hormones in the treatment of delayed gastric emptying in critically ill patients.Glucose metabolism in critically ill patients: are incretins an important player?Glucose absorption in small intestinal diseases.The use of non-insulin anti-diabetic agents to improve glycemia without hypoglycemia in the hospital setting: focus on incretins.Understanding incretins.Practical implementation of incretin-based therapy in hospitalized patients with type 2 diabetes.Nutrition and anabolic pharmacotherapies in the care of burn patients.Incretins: player or stayer?Cardiovascular Safety of Antidiabetic Drugs in the Hospital Setting.Stimulation of the endogenous incretin glucose-dependent insulinotropic peptide by enteral dextrose improves glucose homeostasis and inflammation in murine endotoxemia.The glucoregulatory benefits of glucagon-like peptide-1 (7-36) amide infusion during intensive insulin therapy in critically ill surgical patients: a pilot study.Systematic review of incretin therapy during peri-operative and intensive care
P2860
Q24618730-CE92B735-E8EB-4429-83EE-B385EB3EB9CAQ26821994-54EBD14C-0026-435D-8AFA-2D9C61E199C8Q26995464-6371A99C-EEFF-4D54-8C1A-B701AB5E5D9AQ33741938-4BE6FF01-2C61-41CA-AF91-B87C1352099CQ33751723-4A2209F0-4843-4E84-B64D-94158AFF5DE6Q33754087-73A4A3D9-3245-462D-8846-D0DE30A0C337Q33792390-2CF49467-518C-4B24-83A9-87A98CB6D492Q34153353-B47E23FC-630E-429F-8D8A-2DE82CE46AE4Q35122108-1CF85AB4-6F0E-47DB-9E9C-994AF0E55868Q35559137-33CC0FA7-EA66-4ED8-8A71-B27C50289F50Q35559222-72241DC9-DAE1-43D4-B597-12A7D5C31B99Q35561361-044AAA2D-86C7-4406-995B-76C13B9B276BQ35567284-AFC153FE-4B14-44C0-8B11-25BAFDFEBAC0Q35912987-09476581-8B97-4CE9-B6DE-3C5D7F05BADEQ36281505-B1737B81-963A-41A6-B101-7A5BAAC7FC86Q37193583-7AD5233A-1405-4A8E-AB77-9BBA27643FEEQ37316259-8AA894D2-4ADE-4ED1-A7FF-1BF8DD544186Q37360261-FC8B51E7-94C9-4672-B7A1-DF9007E56C37Q37780914-5CD631C8-F6FD-41EB-9265-FCE46DF5C797Q37781413-C360BFBC-D1AA-487C-8B94-86E299B26B64Q37795946-06DC63F3-5698-4695-AD60-617532EF5962Q37820839-E2926911-32F8-419F-BE4B-594B24E74CD2Q37971830-62D16176-8D4F-4ACD-ABD6-87D6DFA9601CQ38078016-27499727-56C5-4DC7-A5D1-FE4247CEBF92Q38123557-04DF9F86-880C-46F0-94C6-432282B7C76DQ38142955-36118AF4-B47E-4E8D-AB96-319803F946DDQ38185705-DB489A45-7B20-4AA6-BE18-5AF6DBBBC95BQ38187004-32D2FF66-C9BB-4FA0-A3BD-1F1DE3D5FCD0Q38241343-D14F9097-17C3-4259-B699-955D0DA7F398Q38303079-C52DC984-8647-48A8-A941-62E34EBEA3E5Q38326632-7C5339E9-A5CF-40B4-934A-B0C50FDC8F64Q38432296-3A6A4349-5940-482F-878D-E6D9EF00928EQ38683079-044F930D-D4EB-477B-AB9A-D68E4CF6FB7BQ47685514-42F3FF1D-75A4-4775-BAC3-C17BA4C78C26Q49401699-680E8137-4DF6-419A-9232-3D542CA9CD2DQ59126600-9EA4E709-3729-4F98-86F3-ED8C61E6E6EE
P2860
The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The effect of exogenous glucag ...... o-controlled cross over study.
@en
The effect of exogenous glucag ...... o-controlled cross over study.
@nl
type
label
The effect of exogenous glucag ...... o-controlled cross over study.
@en
The effect of exogenous glucag ...... o-controlled cross over study.
@nl
prefLabel
The effect of exogenous glucag ...... o-controlled cross over study.
@en
The effect of exogenous glucag ...... o-controlled cross over study.
@nl
P2093
P2860
P356
P1433
P1476
The effect of exogenous glucag ...... o-controlled cross over study.
@en
P2093
Adam M Deane
Carly M Burgstad
Laura K Besanko
Marianne J Chapman
Michael Horowitz
Robert J L Fraser
P2860
P2888
P356
10.1186/CC7874
P577
2009-05-13T00:00:00Z
P5875
P6179
1030783293